{
    "nct_id": "NCT02709512",
    "official_title": "Randomized, Double-Blind, Phase 2/3 Study in Subjects With Malignant Pleural Mesotheliomato Assess ADI-PEG 20 With Pemetrexed and Cisplatin (ATOMIC-Meso Phase 2/3 Study)",
    "inclusion_criteria": "* Histologically proven unresectable MPM of biphasic or sarcomatoid histology\n* NaÃ¯ve to chemotherapy or immunotherapy\n* ECOG PS 0-1\n* Expected survival of at least 3 months\n* Age 18 years or over (there is no upper age limit)\n* Measurable disease by modified RECIST criteria for MPM for local pleural disease and RECIST 1.1 criteria for metastatic lesions\n* Written (signed and dated) informed consent and must be capable of co-operating with treatment and follow up\n* Adequate hematologic, hepatic, and renal function\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Radiotherapy (except for palliative reasons) in the previous two weeks before study treatment\n* History of unstable cardiac disease\n* Ongoing toxic manifestations of previous treatments\n* Symptomatic brain or spinal cord metastases (patients must be stable for > 1 month post radiotherapy or surgery)\n* Major thoracic or abdominal surgery from which the patient has not yet recovered.",
    "miscellaneous_criteria": ""
}